- Home
- BCG vs LPCN Comparison
BCG vs LPCN Comparison
Compare BCG & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCG
- LPCN
- Stock Information
- Founded
- BCG 2016
- LPCN 1997
- Country
- BCG United States
- LPCN United States
- Employees
- BCG N/A
- LPCN N/A
- Industry
- BCG
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- BCG
- LPCN Health Care
- Exchange
- BCG Nasdaq
- LPCN Nasdaq
- Market Cap
- BCG 45.6M
- LPCN 36.8M
- IPO Year
- BCG N/A
- LPCN N/A
- Fundamental
- Price
- BCG $2.58
- LPCN $5.03
- Analyst Decision
- BCG
- LPCN Strong Buy
- Analyst Count
- BCG 0
- LPCN 1
- Target Price
- BCG N/A
- LPCN $10.00
- AVG Volume (30 Days)
- BCG 76.8K
- LPCN 28.2K
- Earning Date
- BCG 11-14-2024
- LPCN 11-07-2024
- Dividend Yield
- BCG N/A
- LPCN N/A
- EPS Growth
- BCG N/A
- LPCN N/A
- EPS
- BCG N/A
- LPCN N/A
- Revenue
- BCG $161,721,000.00
- LPCN $7,922,926.00
- Revenue This Year
- BCG N/A
- LPCN N/A
- Revenue Next Year
- BCG N/A
- LPCN N/A
- P/E Ratio
- BCG N/A
- LPCN N/A
- Revenue Growth
- BCG N/A
- LPCN N/A
- 52 Week Low
- BCG $1.85
- LPCN $2.44
- 52 Week High
- BCG $16.61
- LPCN $11.79
- Technical
- Relative Strength Index (RSI)
- BCG N/A
- LPCN 50.88
- Support Level
- BCG N/A
- LPCN $4.70
- Resistance Level
- BCG N/A
- LPCN $5.28
- Average True Range (ATR)
- BCG 0.00
- LPCN 0.32
- MACD
- BCG 0.00
- LPCN 0.04
- Stochastic Oscillator
- BCG 0.00
- LPCN 69.53
About BCG Binah Capital Group Inc. Common Stock
Binah Capital Group Inc formerly Wentworth Management Services LLC is a holding company that acquires and manages businesses in the wealth management industry. The company specializes in consolidating independent broker-dealers to capture economies of scale needed to service financial advisors in today's technology-enabled regulatory environment. Wentworth's core philosophy focuses on building long-term, productive relationships with its advisor base.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company. It is focused on oral drug delivery technology for the development of pharmaceutical products focusing on metabolic and endocrine disorders. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, LPCN 1148, and LPCN 1107. The Company has single reportable segment being, research and development for the delivery of drugs using its proprietary delivery technology.